Yes, cenobamate, marketed under the brand name Xcopri, is FDA approved. The U.S. Food and Drug Administration (FDA) approved cenobamate on November 21, 2019, for the treatment of partial-onset seizures in adults.
Cenobamate is a medication used to treat partial-onset seizures in adults. Partial-onset seizures begin in one specific part of the brain and can affect both adults and children. Cenobamate works as an anticonvulsant, helping to reduce the frequency and severity of these seizures.
Cenobamate is available in oral tablet form and is usually taken once daily. The dosage is titrated up gradually over several weeks to minimize side effects and allow the body to adjust to the medication:
It is important to follow the dosing instructions carefully and not to exceed the recommended titration schedule to avoid serious adverse reactions.
Common Side Effects
Serious Side Effects
Cenobamate can cause serious or life-threatening allergic reactions that may affect the liver, blood cells, or other parts of the body. Symptoms to watch for include:
Cenobamate can interact with other medications, including other seizure drugs, opioids, sleeping pills, muscle relaxers, and medications for anxiety. It is crucial to inform your healthcare provider about all the medications you are taking to avoid potential interactions and side effects.
Cenobamate (Xcopri) is an FDA-approved medication for the treatment of partial-onset seizures in adults. Approved on November 21, 2019, it represents a significant advancement in seizure management. Patients should follow their healthcare provider’s instructions closely and report any side effects or mood changes promptly to ensure the safe and effective use of this medication.
In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!